BCLSI
KYTX icon

Bain Capital Life Sciences Investors’s Kyverna Therapeutics KYTX Stock Holding History

Bain Capital Life Sciences Investors’s Portfolio KYTX Stock Details KYTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$26.8M Hold
3,110,000
– – 2.42% 10
2025
Q4 		$29.2M Sell
3,110,000
-258,370
-8% -$1.92M 2.24% 10
2025
Q3 		$20.2M Hold
3,368,370
– – 1.34% 13
2025
Q2 		$10.3M Hold
3,368,370
– – 1.29% 15
2025
Q1 		$6.5M Hold
3,368,370
– – 0.96% 14
2024
Q4 		$12.6M Hold
3,368,370
– – 1.48% 12
2024
Q3 		$16.5M Hold
3,368,370
– – 1.71% 10
2024
Q2 		$25.3M Buy
3,368,370
+204,502
+6% +$3.12M 2.77% 8
2024
Q1 		$78.6M Buy
+3,163,868
New +$88.3M 6.32% 5

Other funds holding KYTX

GGI
GordonMD Global Investments Beverely Hills, California $144M AUM
GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
IHG
Insight Holdings Group New York $1.42B AUM 41.03% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bain Capital Life Sciences Investors's KYTX Position: Q1 2026 in Review

Bain Capital Life Sciences Investors held its Kyverna Therapeutics (KYTX) position steady in Q1 2026 at 3,110,000 shares worth $26.8M. The position accounts for 2.42% of the portfolio, ranked #10.

Bain Capital Life Sciences Investors first reported a position in KYTX in Q1 2024 and has held it in 9 quarters since. The position peaked at $78.6M in Q1 2024. 111 funds tracked by Wall St. Rank hold KYTX as of Q1 2026.

  • Bain Capital Life Sciences Investors held 3,110,000 shares of Kyverna Therapeutics worth $26.8M as of Q1 2026.
  • Bain Capital Life Sciences Investors left its Kyverna Therapeutics share count unchanged in Q1 2026.
  • Kyverna Therapeutics made up 2.42% of Bain Capital Life Sciences Investors's portfolio in Q1 2026, its #10 holding.
  • Bain Capital Life Sciences Investors first reported a position in Kyverna Therapeutics in Q1 2024 and has held it in 9 quarters since.
  • Bain Capital Life Sciences Investors's Kyverna Therapeutics position peaked at $78.6M in Q1 2024.
  • 111 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q1 2026.

Based on Bain Capital Life Sciences Investors's 13F filing for Q1 2026, filed 15 May 2026.